Noonan syndrome management and follow-up: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 16: | Line 16: | ||
===Endocrine and Developmental=== | ===Endocrine and Developmental=== | ||
* Up to 70% of patients with Noonan syndrome have some form of growth delay with mean delay in bone age of 2 years. Although growth hormone supplementation has only been studied in small studies, data suggests improved growth without significant side effects. | |||
* Most studies with long-term follow up suggest that better outcomes are associated with earlier initiation of GH and a longer duration of treatment.<ref name="pmid20876176">{{cite journal| author=Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME et al.| title=Noonan syndrome: clinical features, diagnosis, and management guidelines. | journal=Pediatrics | year= 2010 | volume= 126 | issue= 4 | pages= 746-59 | pmid=20876176 | doi=10.1542/peds.2009-3207 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20876176 }} </ref> | |||
* The largest study involving 65 patients with a mean age at initiation of 11.6 years showed a mean growth of 10.9 cm in boys vs. 9.2 cm in girls with a mean treatment duration of 5.6 years at a dose of 0.33 mg/kg/week.<ref name="pmid19401366">{{cite journal| author=Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J et al.| title=Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 7 | pages= 2338-44 | pmid=19401366 | doi=10.1210/jc.2008-2094 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19401366 }} </ref> In general, doses used in most studies ranged from 0.24-0.35 mg/kg/week.<ref name="pmid20876176">{{cite journal| author=Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME et al.| title=Noonan syndrome: clinical features, diagnosis, and management guidelines. | journal=Pediatrics | year= 2010 | volume= 126 | issue= 4 | pages= 746-59 | pmid=20876176 | doi=10.1542/peds.2009-3207 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20876176 }} </ref> | |||
* Special growth curves for Noonan syndrome have been developed and should be used in plotting growth.<ref name="pmid3780030">{{cite journal| author=Witt DR, Keena BA, Hall JG, Allanson JE| title=Growth curves for height in Noonan syndrome. | journal=Clin Genet | year= 1986 | volume= 30 | issue= 3 | pages= 150-3 | pmid=3780030 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3780030 }} </ref> | |||
* Plotting growth on curves specific for Noonan syndrome is recommended to be done 3 times yearly from birth till age 3 years than yearly after that.<ref name="pmid23312968">{{cite journal| author=Roberts AE, Allanson JE, Tartaglia M, Gelb BD| title=Noonan syndrome. | journal=Lancet | year= 2013 | volume= 381 | issue= 9863 | pages= 333-42 | pmid=23312968 | doi=10.1016/S0140-6736(12)61023-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23312968 }} </ref> | |||
===Renal and Genitourinary=== | ===Renal and Genitourinary=== | ||
Revision as of 00:04, 15 November 2013
|
Noonan syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Noonan syndrome management and follow-up On the Web |
|
American Roentgen Ray Society Images of Noonan syndrome management and follow-up |
|
Risk calculators and risk factors for Noonan syndrome management and follow-up |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Serge Korjian
Overview
Management and Follow-up
A mutlidisciplinary team is often needed in the management of Noonan syndrome. A system-based approach is usually adopted and recommendations are based on the severity of disease manifestations.
Cardiovascular
- Patients with Noonan syndrome require lifetime cardiac follow-up. After initial evaluation including a focused cardiac physical exam, echocardiography, and electrocardiography, follow up is based on work-up findings. If initial work-up is unremarkable, a follow up is recommended every 5 years. [1][2]
- The most common cardiac finding is pulmonary valve stenosis. If mild, only periodic follow-up is recommended. If clinically significant, pulmonary balloon valvuloplasty is recommended in the absence of significant valve dysplasia. With significantly dysplastic valves a pulmonary valvectomy or pulmonary valve homograft during childhood is the first line management. [3]
- The second most common cardiac manifestation of Noonan syndrome is hypertrophic cardiomyopathy. Management is usually similar to most patients with HCM and includes beta-blockers and surgical myomectomy in certain cases with significant outflow obstruction. [3]
Endocrine and Developmental
- Up to 70% of patients with Noonan syndrome have some form of growth delay with mean delay in bone age of 2 years. Although growth hormone supplementation has only been studied in small studies, data suggests improved growth without significant side effects.
- Most studies with long-term follow up suggest that better outcomes are associated with earlier initiation of GH and a longer duration of treatment.[3]
- The largest study involving 65 patients with a mean age at initiation of 11.6 years showed a mean growth of 10.9 cm in boys vs. 9.2 cm in girls with a mean treatment duration of 5.6 years at a dose of 0.33 mg/kg/week.[4] In general, doses used in most studies ranged from 0.24-0.35 mg/kg/week.[3]
- Special growth curves for Noonan syndrome have been developed and should be used in plotting growth.[5]
- Plotting growth on curves specific for Noonan syndrome is recommended to be done 3 times yearly from birth till age 3 years than yearly after that.[1]
Renal and Genitourinary
Hematology and Oncology
Neurologic and Behavioral
Gastrointestinal
Lymphatic
References
- ↑ 1.0 1.1 Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013). "Noonan syndrome". Lancet. 381 (9863): 333–42. doi:10.1016/S0140-6736(12)61023-X. PMID 23312968.
- ↑ van der Burgt I (2007). "Noonan syndrome". Orphanet J Rare Dis. 2: 4. doi:10.1186/1750-1172-2-4. PMC 1781428. PMID 17222357.
- ↑ 3.0 3.1 3.2 3.3 Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME; et al. (2010). "Noonan syndrome: clinical features, diagnosis, and management guidelines". Pediatrics. 126 (4): 746–59. doi:10.1542/peds.2009-3207. PMID 20876176.
- ↑ Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J; et al. (2009). "Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone". J Clin Endocrinol Metab. 94 (7): 2338–44. doi:10.1210/jc.2008-2094. PMID 19401366 Check
|pmid=value (help). - ↑ Witt DR, Keena BA, Hall JG, Allanson JE (1986). "Growth curves for height in Noonan syndrome". Clin Genet. 30 (3): 150–3. PMID 3780030.
Template:Phakomatoses and other congenital malformations not elsewhere classified